Seattle Children's Research Institute, Seattle, Washington.
University of Washington School of Medicine, Seattle, Washington.
Gastroenterology. 2021 Jun;160(7):2367-2382.e1. doi: 10.1053/j.gastro.2021.02.052. Epub 2021 Feb 25.
BACKGROUND & AIMS: Both existing clinical criteria and genetic testing have significant limitations for the diagnosis of Wilson disease (WD), often creating ambiguities in patient identification and leading to delayed diagnosis and ineffective management. ATP7B protein concentration, indicated by direct measurement of surrogate peptides from patient dried blood spot samples, could provide primary evidence of WD. ATP7B concentrations were measured in patient samples from diverse backgrounds, diagnostic potential is determined, and results are compared with biochemical and genetic results from individual patients.
Two hundred and sixty-four samples from biorepositories at 3 international and 2 domestic academic centers and 150 normal controls were obtained after Institutional Review Board approval. Genetically or clinically confirmed WD patients with a Leipzig score >3 and obligate heterozygote (carriers) from affected family members were included. ATP7B peptide measurements were made by immunoaffinity enrichment mass spectrometry.
Two ATP7B peptides were used to measure ATP7B protein concentration. Receiver operating characteristics curve analysis generates an area under the curve of 0.98. ATP7B peptide analysis of the sequence ATP7B 887 was found to have a sensitivity of 91.2%, specificity of 98.1%, positive predictive value of 98.0%, and a negative predictive value of 91.5%. In patients with normal ceruloplasmin concentrations (>20 mg/dL), 14 of 16 (87.5%) were ATP7B-deficient. In patients without clear genetic results, 94% were ATP7B-deficient.
Quantification of ATP7B peptide effectively identified WD patients in 92.1% of presented cases and reduced ambiguities resulting from ceruloplasmin and genetic analysis. Clarity is brought to patients with ambiguous genetic results, significantly aiding in noninvasive diagnosis. A proposed diagnostic score and algorithm incorporating ATP7B peptide concentrations can be rapidly diagnostic and supplemental to current Leipzig scoring systems.
现有的临床标准和基因检测对威尔逊病(WD)的诊断均存在显著局限性,常导致患者识别不明确,进而延误诊断和治疗。ATP7B 蛋白浓度可通过直接测量患者干血斑样本中的替代肽来指示,可提供 WD 的主要证据。本研究在来自 3 个国际和 2 个国内学术中心的生物库中检测了 264 例患者样本,并对其进行了诊断潜力的测定,结果与个体患者的生化和基因结果进行了比较。
在获得机构审查委员会批准后,我们从国际的 3 个学术中心和国内的 2 个学术中心的生物库中获取了 264 例样本,以及 150 例正常对照。纳入了遗传或临床确诊的 WD 患者(莱比锡评分>3 分和来自受影响家族成员的杂合子(携带者))。采用免疫亲和富集质谱法检测 ATP7B 肽。
本研究使用 2 个 ATP7B 肽来测量 ATP7B 蛋白浓度。受试者工作特征曲线分析产生的曲线下面积为 0.98。对 ATP7B 887 序列的 ATP7B 肽分析发现,其敏感性为 91.2%,特异性为 98.1%,阳性预测值为 98.0%,阴性预测值为 91.5%。在正常铜蓝蛋白浓度(>20mg/dL)的患者中,16 例中有 14 例(87.5%)ATP7B 缺乏。在无明确遗传结果的患者中,94%的患者 ATP7B 缺乏。
ATP7B 肽的定量分析可有效识别 92.1%的患者,减少了铜蓝蛋白和遗传分析带来的不确定性。对遗传结果不明确的患者提供了明确的诊断,极大地辅助了非侵入性诊断。一个包含 ATP7B 肽浓度的拟议诊断评分和算法可以快速诊断,并补充现有的莱比锡评分系统。